A comprehensive review of SHP2 and its role in cancer

MD Asmamaw, XJ Shi, LR Zhang, HM Liu - Cellular Oncology, 2022 - Springer
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …

Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application

X Yuan, H Bu, J Zhou, CY Yang… - Journal of medicinal …, 2020 - ACS Publications
SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …

Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer

MJ LaMarche, M Acker, A Argintaru… - Journal of medicinal …, 2020 - ACS Publications
SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …

Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

Y Song, M Zhao, H Zhang, B Yu - Pharmacology & therapeutics, 2022 - Elsevier
Phosphorylation is a reversible post-translational modification regulated by phosphorylase
and dephosphorylase to mediate important cellular events. Src homology-2-containing …

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

DL Kerr, F Haderk, TG Bivona - Current opinion in chemical biology, 2021 - Elsevier
The nonreceptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) integrates
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …

Strategies targeting protein tyrosine phosphatase SHP2 for cancer therapy

Y Song, S Wang, M Zhao, X Yang… - Journal of medicinal …, 2022 - ACS Publications
The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic
target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery …

Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein

M Wang, J Lu, M Wang, CY Yang… - Journal of medicinal …, 2020 - ACS Publications
Src homology 2 domain-containing phosphatase 2 (SHP2) is an attractive therapeutic target
for human cancers and other human diseases. Herein, we report our discovery of potent …

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

JR LaRochelle, M Fodor, V Vemulapalli… - Nature …, 2018 - nature.com
Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2,
result in developmental disorders and act as oncogenic drivers in patients with hematologic …

[HTML][HTML] Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Z Song, M Wang, Y Ge, XP Chen, Z Xu, Y Sun… - … Pharmaceutica Sinica B, 2021 - Elsevier
Src homology containing protein tyrosine phosphatase 2 (SHP2) represents a noteworthy
target for various diseases, serving as a well-known oncogenic phosphatase in cancers. As …

Turn and face the strange: § a new view on phosphatases

M Köhn - ACS central science, 2020 - ACS Publications
Phosphorylation as a post-translational modification is critical for cellular homeostasis.
Kinases and phosphatases regulate phosphorylation levels by adding or removing …